At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Creatine Monohydratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study
In Brief
A Phase 2 clinical trial evaluating Creatine Monohydrate for Huntington's Disease. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of this clinical trial is to extend the Pre-Crest study (Protocol # (NCT00592995) to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's Disease (HD) and to assess whether biomarkers responsive to creatine in symptomatic individuals are informative in premanifest individuals over a longer duration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington's Disease
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedAug 2011
Primary CompletionSep 2012
TodayJul 2026
First PostedAug 8, 2011
Enrollment StartMay 1, 2009
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.9 years ago
Interventions
Creatine Monohydratedrug
Up to 30 grams daily creatine monohydrate